Journal article · 2026 · Open access
Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial
JAMA · Published 8 October 2026 · DOI 10.1001/jama.2026.18828
In brief
“Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial” is a 2026 journal article by Brage Brakedal and 40 co-authors, published in JAMA. OpenAlex counts 2 citations as of 17 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 5.94
- References
- 22
- Authors
- 41
Abstract
Importance: Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown. Objective: To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared with placebo. Design, Setting, and Participants: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway. Eligible participants were patients aged 35 years or older with Parkinson disease diagnosed within 2 years before enrollment, Hoehn and Yahr disease stage less than 3, abnormal dopamine transporter scintigraphy findings confirming dopaminergic nigrostriatal denervation, and stable dopaminergic treatment before enrollment. Of 537 screened individuals, 410 were randomized from May 6, 2020, to June 20, 2024, and 393 were included in the primary analysis. Final follow-up was completed on June 19, 2025. Interventions: Patients were randomized to receive oral nicotinamide riboside, 500 mg twice daily (n = 206), or matching placebo (n = 204) for 52 weeks. Main Outcomes and Measures: The primary outcome was change from baseline to week 52 in the Movement Disorder Society Unified Parkinson Disease Rating Scale total score (MDS-UPDRS parts I-III; range, 0-236, with higher scores indicating more severe disease; clinically important differences for improvement and worsening, 6.7 and 5.2 points, respectively), analyzed using a mixed model for repeated measures. The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS; range, 0-360, with higher scores indicating greater nonmotor symptom burden). Results: Among the 393 participants in the primary analysis, the mean age was 65.6 (SD, 9.4) years and 133 (34%) were female. At week 52, the total MDS-UPDRS score increased by 2.45 (95% CI, 0.80-4.10) points with nicotinamide riboside and decreased by 0.27 (95% CI, -1.95 to 1.40) points with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points; P = .02), favoring placebo. Of the 5 prespecified key secondary outcomes, 4 showed no significant difference, but nonmotor symptom burden worsened more with nicotinamide riboside (NMSS score adjusted mean difference, 4.22 [95% CI, 1.07-7.37] points; P = .009). Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population. Conclusions and Relevance: Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Brakedal, B., SKEIE, G. O., Derad, C., Alstadhaug, K. B., Anundskås, I., Berven, H., Biermann, M., Bjørnarå, K. A., Cleuren, Y. N. T., Dalbro, S. E. J., Eidelberg, D., Foldnes, K., Fortes, G., Haugarvoll, K., Herlofson, K., Hustad, E., HogenEsch, R., Johanson, G. A. S., Johnsen, S. H., . . . Tzoulis, C. (2026). Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.18828
MLA 9
Brakedal, Brage, et al. “Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.18828.
Chicago
Brakedal, Brage, GEIR OLVE SKEIE, Carlotta Derad, Karl Bjørnar Alstadhaug, Ingunn Anundskås, Haakon Berven, Martin Biermann, et al. 2026. “Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.18828.
Harvard
Brakedal, B. et al. (2026) ‘Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.18828.
IEEE
B. Brakedal et al., “Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.18828.
BibTeX
@article{brakedal2026nicotinamide,
title = {{Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial}},
author = {Brakedal, Brage and SKEIE, GEIR OLVE and Derad, Carlotta and Alstadhaug, Karl Bjørnar and Anundskås, Ingunn and Berven, Haakon and Biermann, Martin and Bjørnarå, Kari Anne and Cleuren, Yamila N. Torres and Dalbro, Solveig E J and Eidelberg, David and Foldnes, Kjartan and Fortes, Gabriela and Haugarvoll, Kristoffer and Herlofson, Karen and Hustad, Eldbjørg and HogenEsch, R.I. and Johanson, Gard Aasmund Skulstad and Johnsen, Stein Harald and Johansen, Krisztina Kunszt and Kverneng, Simon Ulvenes and Labusau, Aliaksei and Lie, Ingeborg Haugesag and Lilleng, Hallvard and Lundervold, Katarina and Lundqvist, Christofer and Ma, Yilong and McCann, Adrian and Njølstad, Tormund Haugland and Pihlstrøm, Lasse and others},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.18828},
url = {https://doi.org/10.1001/jama.2026.18828}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- nicotinamide riboside
- Parkinson's disease
- early-stage Parkinson's disease
- NAD+ precursors
- disease-modifying therapy
- MDS-UPDRS
- Unified Parkinson's Disease Rating Scale
- dopamine transporter imaging
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Brakedal, B., SKEIE, G. O., Derad, C., Alstadhaug, K. B., Anundskås, I., Berven, H., Biermann, M., Bjørnarå, K. A., Cleuren, Y. N. T., Dalbro, S. E. J., Eidelberg, D., Foldnes, K., Fortes, G., Haugarvoll, K., Herlofson, K., Hustad, E., HogenEsch, R., Johanson, G. A. S., Johnsen, S. H., . . . Tzoulis, C. (2026). Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.18828
How many times has this paper been cited?
2 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Brage Brakedal, GEIR OLVE SKEIE, Carlotta Derad, Karl Bjørnar Alstadhaug, Ingunn Anundskås, Haakon Berven, Martin Biermann, Kari Anne Bjørnarå, Yamila N. Torres Cleuren, Solveig E J Dalbro, David Eidelberg, Kjartan Foldnes and 29 more.
What is the DOI of this paper?
10.1001/jama.2026.18828, permanently at https://doi.org/10.1001/jama.2026.18828. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.